Monlunabant

DB21537InvestigationalSmall molecule

Monlunabant is a small molecule drug. The usage of the INN stem '-nabant' in the name indicates that Monlunabant is a cannabinoid receptor antagonist. Monlunabant is under investigation in clinical... Monlunabant is under investigation in clinical trial NCT06542536 (A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men).

Mechanism: Pharmacologically active on Cannabinoid receptor 1
Curator reviewed
Formula / weight: C₂₆H₂₂ClF₃N₆O₃S · 591.01 g/mol (avg)
Code names: MRI-1891 · MRI-1891, (S)-

Resolves to

Compound

UNII4G8X27X87ACAS2712480-46-9ChEMBLCHEMBL5435445

Structure

InChIKeyGYJPQNPVIJXXTA-JOCHJYFZSA-NSMILES[H][C@@]1(CN(N=C1C1=CC=C(Cl)C=C1)C(NS(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)=NC(=N)NC(C)=O)C1=CC=CC=C1

Targets

P21554CNR1

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Monlunabant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account